4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Genital Herpes by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 16 ongoing clinical trials involving Genital Herpes
Of the 16 trials,7 trials are in Phase I/II
Furthermore, 4 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Genital Herpes by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Genital Herpes, an Infectious Disease. The largest number of ongoing clinical trials for Genital Herpes is conducted in Asia-Pacific and Europe region. Middle East and Africa, North America and South and Central America are among other prominent regions engaged in Genital Herpes -related drug trials.

Genital Herpes related clinical trial sponsor

Maruho Co Ltd, Tehran University of Medical Sciences, University of Sao Paulo General Hospital and Labolife Belgium Sprl are few notable clinical trial sponsors involved in Genital Herpes . A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Genital Herpes

Valacyclovir hydrochloride (Valtrex, Zelitrex, Valherpes, Virval, Zimivir, Rapivir), Dimepranol acedoben also known as Inosine acedoben dimepranol or Inosine pranobex (Groprinosin) and Famciclovir (Famvir/Famgen/Oravir/Afamcivir) are among the key marketed drugs involving Genital Herpes.

Valacyclovir hydrochloride (Valtrex, Zelitrex, Valherpes, Virval, Zimivir, Rapivir) is an antiviral agent. It functions via 5 DNA Polymerase (EC 2.7.7.7) Inhibitor mechanism of action. Valacyclovir hydrochloride is formulated as film coated tablets, tablets, coated tablets and granules for oral route of administration. Valacyclovir hydrochloride was first approved in 1995 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including GlaxoSmithKline LLC.

Dimepranol acedoben also known as Inosine acedoben dimepranol or Inosine pranobex (Groprinosin) is a combinatinon of inosine, acetamidobenzoic acid and dimethylaminoisopropanol acts as an antiviral agent. It functions via T Cell Differentiation Antigen CD6 (T12 or TP120 or CD6) Activator mechanism of action. Dimepranol acedoben is formulated as tablets for oral route of administration. Inosine pranobex is indicated for the treatment of immunodeficiency states caused by viral infections in patients with normal and compromised immune systems, including disease caused by the virus herpes simplex subacute sclerosing panencephalitis. Dimepranol acedoben was first approved in 2008 and is marketed solely in Russia by Gedeon Richter - RUS.